















	OL92	$IC_{50} = 0.28 \text{ nM}$	1,2
	OL135	$IC_{50} = 2.1 \text{ nM}$	1,2
	7	$K_i = 1.9 \text{ nM}, IC_{50} = 30 \text{ nM}$	3
	8	$K_i = 22 \text{ nM}, IC_{50} = 100 \text{ nM}$	4
	9	$K_i = 0.29 \text{ nM}$	5
	10c	$K_i = 2.6 \text{ nM}, IC_{50} = 10 \text{ nM}$	6
	11h	$K_i = 1 \text{ nM}, IC_{50} = 20 \text{ nM}$	6
	11j	$K_i = 1 \text{ nM}, IC_{50} = 0.4 \text{ nM}$	6
	12h	$K_i = 3 \text{ nM}$	6
	13g	$K_i = 0.75 \text{ nM}, IC_{50} = 0.7 \text{ nM}$	6
	14b	$K_i = 3.2 \text{ nM}$	6

	WO2007061862 (Janssen)	$IC_{50} = 1.8/27 \text{ nM}$ (hFAAH)	7
	WO2007140005 (Janssen)	$IC_{50} = 4/7 \text{ nM}$ (hFAAH)	8
	18	$IC_{50} = 3.6 \text{ nM}$ (hFAAH)	9
	URB524	$IC_{50} = 63 \text{ nM}$	10
	URB597	$IC_{50} = 4.6 \text{ nM}$	11
	MAK2015	$IC_{50} = 1.1 \text{ nM}$	12
	23	$IC_{50} = 6.9 \text{ nM}$	13
	25	$IC_{50} = 0.74 \text{ nM}$	14
	ST4070	$IC_{50} = 9 \text{ nM}$	15
	BMS1	$IC_{50} = 1.7 \text{ nM}$	16
	34	$IC_{50} = 0.27 \text{ nM}$	17

	ST4020	$IC_{50} < 10 \text{ nM}$	18
	JZL195	$IC_{50} = 2 \text{ nM}$	19
	WO2006088075 (Astellas)	$IC_{50} = 0.093 \text{ nM}$	20
	WO2010007966 (Astellas)	$IC_{50} = 0.047 \text{ nM}$	21
	URB880	$IC_{50} = 0.63 \text{ nM}$	22
	JNJ1661010	$IC_{50} = 34 \text{ nM}$	23
	48	$IC_{50} = 1.35 \text{ nM}$	23
	WO2006054652 (Takeda)	$IC_{50} = 10 \text{ nM}$	24
	PF750	$IC_{50} = 16 \text{ nM}$, $K_{inact}/K_i = 791 \text{ M}^{-1}\text{s}^{-1}$	25
	PF3845	$K_{inact}/K_i = 14310 \text{ M}^{-1}\text{s}^{-1}$	26

	WO2008023720 (Astellas)	$IC_{50} = 0.093 \text{ nM}$ (hFAAH)	27
	WO2009109743 (Vernalis)	$IC_{50} = 3 \text{ nM}$ (hFAAH)	28
	WO2009151991 (Merck)	$IC_{50} = 0.47 \text{ nM}$	29
	WO2009152025 (Merck)	$IC_{50} = 6.3 \text{ nM}$	30
	96	$IC_{50} = 18 \text{ nM}$ (hFAAH)	31
	98	$IC_{50} = 0.45 \text{ nM}$	32
	99	$IC_{50} = 6.1 \text{ nM}$	32

(1) Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. *J. Pharmacol. Exp. Ther.* **2004**, *311*, 441-448.

(2) Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaraes, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. *J. Med. Chem.* **2005**, *48*, 1849-1856.

(3) DeMartino, J. K.; Garfunkle, J.; Hochstatter, D. G.; Cravatt, B. F.; Boger, D. L. Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hydrolase. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5842-5846.

(4) Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apodaca, R. L.; Breitenbucher, J. G.; Cravatt, B. F.; Boger, D. L. Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. *J. Med. Chem.* **2007**, *50*, 1058-1068.

(5) Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1423-1428.

(6) Hardouin, C.; Kelso, M. J.; Romero, F. A.; Rayl, T. J.; Leung, D.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. *J. Med. Chem.* **2007**, *50*, 3359-3368.

(7) Apodaca, R. L.; Breitenbucher, J. G.; Epperson, M. T.; Fried, A. K.; Pippel, D. J.; Seierstad, M. 2-keto-oxazoles as modulators of fatty acid amide hydrolase. WO2007061862 2007.

(8) Apodaca, R. L.; Breitenbucher, J. G.; Chambers, A. L.; Seierstad, M.; Xiao, W. Oxazolyl piperidine modulators of fatty acid amide hydrolase. WO2007140005, 2007.

(9) Timmons, A.; Seierstad, M.; Apodaca, R.; Epperson, M.; Pippel, D.; Brown, S.; Chang, L.; Scott, B.; Webb, M.; Chaplan, S. R.; Breitenbucher, J. G. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2109-2113.

(10) Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J. Med. Chem.* **2003**, *46*, 2352-2360.

(11) Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. *J. Med. Chem.* **2004**, *47*, 4998-5008.

(12) Makriyannis, A.; Nikas, S. P.; Alapafuja, S. O.; Shukla, V. G. Monoacylglycerol lipase inhibitors modulation of cannabinoid activity. US 2011/0039874 2011.

(13) Minkkila, A.; Myllymaki, M. J.; Saario, S. M.; Castillo-Melendez, J. A.; Koskinen, A. M. P.; Fowler, C. J.; Leppanen, J.; Nevalainen, T. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. *Eur. J. Med. Chem.* **2009**, *44*, 2994-3008.

(14) Myllymaki, M. J.; Kasnanen, H.; Kataja, A. O.; Lahtela-Kakkonen, M.; Saario, S. M.; Poso, A.; Koskinen, A. M. P. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields. *Eur. J. Med. Chem.* **2009**, *44*, 4179-4191.

(15) Gattinoni, S.; De Simone, C.; Dallavalle, S.; Fezza, F.; Nannei, R.; Amadio, D.; Minetti, P.; Quattrociocchi, G.; Caprioli, A.; Borsini, F.; Cabri, W.; Penco, S.; Merlini, L.; Maccarrone, M. Enol Carbamates as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) Endowed with High Selectivity for FAAH over the Other Targets of the Endocannabinoid System. *ChemMedChem* **2010**, *5*, 357-360.

(16) Sit, S.-Y.; Xie, K. Bisarylimidazoyl fatty acid amide hydrolase inhibitors. WO2002087569, 2002.

(17) Sit, S. Y.; Conway, C. M.; Xie, K.; Bertekap, R.; Bourin, C.; Burris, K. D. Oxime Carbamate-Discovery of a series of novel FAAH inhibitors. *Bioorg. Med. Chem. Lett.*, **20**, 1272-1277.

- (18) Minetti, P.; Cabri, W.; Borsini, F.; Caprioli, A.; Penco, S.; Dallavalle, S.; Merlini, L.; Maccarrone, M. Oxime carbamoyl derivatives as modulators of fatty acid amides hydrolase. WO2009138416, 2009.
- (19) Long, J. Z.; Nomura, D. K.; Vann, R. E.; Walentiny, D. M.; Booker, L.; Jin, X.; Burston, J. J.; Sim-Selley, L. J.; Lichtman, A. H.; Wiley, J. L.; Cravatt, B. F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 20270-20275.
- (20) Ishii, T.; Sugane, T.; Maeda, J.; Narasaki, F.; Kakefuda, A.; Sato, K.; Takahashi, T.; Kanayama, T.; Saitoh, C.; Suzuki, J.; Kanai, C. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative. WO2006088075, 2006.
- (21) Aoki, S.; Munakata, R.; Kawano, N.; Samizu, K.; Oka, H.; Ishii, T.; Sugane, T. Azole compound. WO2010007966 2006.
- (22) Mor, M.; Lodola, A.; Rivara, S.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Piersanti, G.; Clapper, J. R.; King, A. R.; Tarzia, G.; Piomelli, D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: Modulation at the N-portion of biphenyl-3-yl alkylcarbamates. *J. Med. Chem.* **2008**, *51*, 3487-3498.
- (23) Keith, J. M.; Apodaca, R.; Xiao, W.; Seierstad, M.; Pattabiraman, K.; Wu, J. J.; Webb, M.; Karbarz, M. J.; Brown, S.; Wilson, S.; Scott, B.; Tham, C. S.; Luo, L.; Palmer, J.; Wennerholm, M.; Chaplan, S.; Breitenbucher, J. G. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4838-4843.
- (24) Matsumoto, T.; Kori, M.; Miyazaki, J.; Kiyota, Y. Amide compound. WO2006054652, 2006.
- (25) Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Nomanbhoy, T. K.; Alexander, J. P.; Cravatt, B. F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. *Biochemistry* **2007**, *46*, 13019-13030.
- (26) Ahn, K.; Johnson, D. S.; Mileni, M.; Beidler, D.; Long, J. Z.; McKinney, M. K.; Weerapana, E.; Sadagopan, N.; Liimatta, M.; Smith, S. E.; Lazerwith, S.; Stiff, C.; Kamtekar, S.; Bhattacharya, K.; Zhang, Y. H.; Swaney, S.; Van Becelaere, K.; Stevens, R. C.; Cravatt, B. F. Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain. *Chem. Biol.* **2009**, *16*, 411-420.
- (27) Ishii, T.; Sugane, T.; Kakefuda, A.; Takahashi, T.; Kanayama, T.; Sato, K.; Kuriwaki, I.; Kitada, C.; Suzuki, J. Urea compound or salt thereof. WO2008023720, 2008.
- (28) Roughley, S.; Walls, S.; Hart, T.; Parsons, R.; Brough, P.; Graham, C.; Macias, A. Azetidine derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof. WO2009109743, 2009.
- (29) Lin, L. S.; Chang, L. L.; Chobanian, H.; Nargund, R. P. Pyrazole derivatives useful as inhibitors of FAAH. WO2009151991, 2009.
- (30) Lin, L. S.; Chioda, M. D.; Liu, P.; Nargund, R. P. Imidazole derivatives useful as inhibitors of FAAH. WO2009152025, 2009.
- (31) Wang, X. Q.; Sarris, K.; Kage, K.; Zhang, D.; Brown, S. P.; Kolasa, T.; Surowy, C.; El Kouhen, O. F.; Muchmore, S. W.; Brioni, J. D.; Stewart, A. O. Synthesis and Evaluation of Benzothiazole-Based Analogues as Novel, Potent, and Selective Fatty Acid Amide Hydrolase Inhibitors. *J. Med. Chem.* **2009**, *52*, 170-180.
- (32) Minkkila, A.; Savinainen, J. R.; Kasnanen, H.; Xhaard, H.; Nevalainen, T.; Laitinen, J. T.; Poso, A.; Leppanen, J.; Saario, S. M. Screening of Various Hormone-Sensitive Lipase Inhibitors as Endocannabinoid-Hydrolyzing Enzyme Inhibitors. *ChemMedChem* **2009**, *4*, 1253-1259.

